Susan P. Borden
Susan P. Borden is chairman of Bumper Investments Ltd., a private investment company founded 55 years ago in Alberta, Canada. Today, Bumper has three major offices: In Calgary for oil and gas exploration and production for North America; in New York for venture capital investments in targeted bio-tech, high tech and educational domains; and in Lyon, France for property development. Prior to joining Bumper, Mrs. Borden was the Senior Energy Fellow at the Aspen Institute and the Vice Chairman of Common Cause. In addition to serving on the Board of Managers for Promosome, she currently is a Director of Intellisis and a trustee of both The Neurosciences Institute and Bennington College. She is chairman of The Bumper Foundation.
Loren A. Busby
Loren A. Busby, CFA has been involved in the venture capital industry as an investor and entrepreneur for over 20 years. Currently, under the moniker Cresco Advisors LLC, Ms. Busby provides a variety of financial and advisory services to fund managers and small businesses. She is working with several growth-stage businesses as their CFO and strategic advisor, including Promosome LLC. Ms. Busby also acts as a special advisor to established venture funds, actively investing fund-of-funds, and emerging managers. From 2005-2010, Ms. Busby was a Partner at NGN Capital, a $400 million healthcare-focused venture fund where she was involved in raising and investing in cross-border pharma/medical device transactions over two fund cycles. Prior to NGN Capital, she was with Walden Capital Partners L.P. where she sourced and managed several small- to mid-size investments in the manufacturing, distribution and technology sectors. In the mid-1990s, Ms. Busby was an Associate at Princeton University Investment Company and Nassau Capital LLC, where she worked on direct investments in middle-market companies and funds-of-funds investments on behalf of Princeton's endowment. At the onset of her career, Ms. Busby worked at Thomson Financial/Venture Economics, then publisher of Venture Capital Journal, where she provided consulting services to Fortune 500 executives who required a window on venture-backed technology. She also had programming and marketing roles in the development of several database products, including the venerable VentureExpert. Ms. Busby earned a B.S. from Central Connecticut State University and an M.B.A. from Columbia University (McCain Scholar). She is a member of the New York Society of Security Analysts, where she served as Chairman and Vice-Chairman of its Alternative Investments Committee with 450 members. She is also a Chartered Financial Analyst.
John R. Costantino
John R. Costantino is a Managing General Partner at NGN Capital with 25 years of private equity experience. He was formerly a Partner of Walden Partners as well as Costantino, Melamede & Greenberg, an investment partnership which specialized in acquiring and managing growth businesses. Mr. Costantino was also Senior Executive Vice President & COO and a Director of Conair, a leading personal care company with over $1 billion of revenues as well as President and a Managing Director of Integrated Resources Acquisition, a leveraged buyout firm. He started his career at Touche Ross, a major accounting firm where he became the firm's managing tax partner in New York. Mr. Costantino is a trustee of General Electric's family of mutual funds. He holds a B.S. and J.D. from Fordham University and is also a C.P.A. Mr. Costantino also serves on the Board of Directors of ACT Biotech, a spin-out from Bayer Pharmaceuticals, Artisan Pharma, Inc. and Medrium Corporation. He continues to participate and has served on a number of other domestic and international boards.
William J. Gedale
Mr. Gedale is a Senior Advisor and co-founder of NGN Capital, and has been in the investment business since 1965. Mr. Gedale joined NGN from Mount Everest Advisors, which he founded in 1996. He has served as an investment advisor to individuals and as a full time consultant to Warburg-Pincus Capital Management, the world's largest venture capital firm. In this capacity, he initiated the $140 million dollar financing of ZymoGenetics. From 1969 to 1995 Mr. Gedale, was associated with General American Investors, during his tenure he helped arrange the $350 million funding by Sandoz (Novartis) of the Scripps Research Institute and the $40 million funding of the Neuroscience Research Institute of La Jolla, California (of which he is a trustee).
James T. Jahnke
Mr. Jahnke is the Managing Director of Private Equity at Palisade Capital Management, LLC. He and his team is responsible for portfolio monitoring and financial analysis of existing investments, valuation determination, deal structuring and due diligence of new investments. Mr. Jahnke, together with the Principals of Palisade Capital, is responsible for the sourcing of new private equity investments. Mr. Jahnke joined Palisade Capital in 2005.
Prior to joining Palisade, Mr. Jahnke held various positions over an eighteen year period at Chrysler and DaimlerChrysler in Control, Treasury, Merger and Acquisitions and Investor Relations. Mr. Jahnke received his M.B.A. from the University of Chicago Graduate School of Business and is a graduate of the University of Denver.
John F. Manzello
Mr. Manzello was appointed CEO of Promosome in 2007, bringing nearly 20 years of executive and director level experience in the biopharmaceutical industry with a concentration on business development and strategic alliances for the introduction of novel technologies. Prior to joining Promosome, Mr. Manzello was at San Diego's Althea Technologies. While at Althea, Mr. Manzello initiated and directed business development efforts supporting late phase biopharmaceutical production. Prior to Althea, Mr. Manzello utilized his talents and gained significant industry experience as Director of Business Development at Cohesive Technologies, Director of Commercial Development at Genzyme Transgenics and Director of Biopharmaceutical Services at Primedica Corporation. Mr. Manzello remains an active member of several biotechnology industry organizations and also serves on the Board of Directors of Recopharma AB, a Stockholm based biotherapeutic company.
Edward R. Robinson
Mr. Robinson brings to Promosome nearly 30 years in life sciences, with experience in cell culture, fine chemistry and industrial biotechnology. Having served as President of Lonza Biologics Inc., President of Solutia's Pharmaceutical Services Division, Executive Vice President of Pharma and Biopharmaceuticals for Cambrex Corporation, and Vice President of Asia Pacific for Genencor International, Mr. Robinson is well placed to assist in the growth of Promosome's business. As an independent advisor or non-executive board director, Mr. Robinson has assisted a number of life science and investment companies in the US and Europe in the areas of business development, strategy and corporate development. Mr. Robinson is a graduate of Clarkson University, holds an MBA from the Rochester Institute of Technology and also attended the Executive Management Program at Pennsylvania State University.